Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

医学 双特异性抗体 耐火材料(行星科学) 内科学 淋巴瘤 抗体 癌症研究 肿瘤科 免疫学 单克隆抗体 天体生物学 物理
作者
Catherine Thiéblemont,Tycel Phillips,Hervé Ghesquières,Chan Y. Cheah,Michael Roost Clausen,David Cunningham,Young Rok,Tatyana Feldman,Robin Gasiorowski,Wojciech Jurczak,Tae Min Kim,David Lewis,Marjolein van der Poel,Michelle Poon,Mariana Cota Stirner,Nurgul Kilavuz,Christopher Chiu,Menghui Chen,Mariana Sacchi,Brian Elliott
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (12): 2238-2247 被引量:481
标识
DOI:10.1200/jco.22.01725
摘要

PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. PATIENTS AND METHODS In the dose-expansion cohort of a phase I/II study (ClinicalTrials.gov identifier: NCT03625037 ), adults with relapsed or refractory CD20 + large B-cell lymphoma and at least two prior therapy lines (including anti-CD20 therapies) received subcutaneous epcoritamab in 28-day cycles (once weekly step-up doses in weeks 1-3 of cycle 1, then full doses once weekly through cycle 3, once every 2 weeks in cycles 4-9, and once every 4 weeks in cycle 10 and thereafter) until disease progression or unacceptable toxicity. The primary end point was overall response rate by the independent review committee. RESULTS As of January 31, 2022, 157 patients were treated (median age, 64 years [range, 20‐83]; median of three [range, 2-11] prior therapy lines; primary refractory disease: 61.1%; prior chimeric antigen receptor (CAR) T-cell exposure: 38.9%). At a median follow-up of 10.7 months, the overall response rate was 63.1% (95% CI, 55.0 to 70.6) and the complete response rate was 38.9% (95% CI, 31.2 to 46.9). The median duration of response was 12.0 months (among complete responders: not reached). Overall and complete response rates were similar across key prespecified subgroups. The most common treatment-emergent adverse events were cytokine release syndrome (49.7%; grade 1 or 2: 47.1%; grade 3: 2.5%), pyrexia (23.6%), and fatigue (22.9%). Immune effector cell–associated neurotoxicity syndrome occurred in 6.4% of patients with one fatal event. CONCLUSION Subcutaneous epcoritamab resulted in deep and durable responses and manageable safety in highly refractory patients with large B-cell lymphoma, including those with prior CAR T-cell exposure.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
宝z发布了新的文献求助10
1秒前
斯文败类的应助被淡定采纳,获得10
1秒前
wxm的应助被California采纳,获得10
1秒前
ohh完成签到,获得积分10
1秒前
STaoY完成签到,获得积分10
1秒前
1秒前
1秒前
Rtian发布了新的文献求助10
2秒前
May发布了新的文献求助10
2秒前
搜集达人的应助被Ava采纳,获得10
2秒前
2秒前
科研通AI6.4的应助被CClaire采纳,获得10
2秒前
乐事小黄瓜完成签到,获得积分10
2秒前
李健的应助被米饭采纳,获得10
2秒前
程绪洋完成签到 ,获得积分10
3秒前
就爱吃抹茶完成签到 ,获得积分10
3秒前
nemo711完成签到,获得积分10
3秒前
SciGPT的应助被SGLY采纳,获得10
3秒前
ZJB完成签到,获得积分10
3秒前
3秒前
鸟鸣完成签到,获得积分10
4秒前
4秒前
4秒前
4秒前
4秒前
4秒前
哈哈完成签到,获得积分10
4秒前
yoowt完成签到,获得积分10
4秒前
5秒前
5秒前
5秒前
笨笨听寒完成签到,获得积分10
5秒前
5秒前
Always发布了新的文献求助10
5秒前
风中怜雪完成签到,获得积分10
5秒前
卡比兽mini完成签到 ,获得积分10
5秒前
pqdds完成签到,获得积分10
6秒前
高小高完成签到 ,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159929
求助须知:如何正确求助?哪些是违规求助? 9555266
关于积分的说明 21726335
捐赠科研通 7749807
什么是DOI,文献DOI怎么找? 3427310
关于科研通互助平台的介绍 2552391
邀请新用户注册赠送积分活动 2471654